GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery.
about
Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics.Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells.Conformational biosensors reveal allosteric interactions between heterodimeric AT1 angiotensin and prostaglandin F2α receptors.Commentary: Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.
P2860
GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
GPCR heterodimers: asymmetries ...... ew targets for drug discovery.
@en
type
label
GPCR heterodimers: asymmetries ...... ew targets for drug discovery.
@en
prefLabel
GPCR heterodimers: asymmetries ...... ew targets for drug discovery.
@en
P2860
P356
P1476
GPCR heterodimers: asymmetries ...... new targets for drug discovery
@en
P2093
Stéphane A Laporte
Terence E Hébert
P2860
P304
P356
10.1111/BPH.12040
P407
P577
2013-03-01T00:00:00Z